166 related articles for article (PubMed ID: 7776837)
1. An efficient new cannabinoid antiemetic in pediatric oncology.
Abrahamov A; Abrahamov A; Mechoulam R
Life Sci; 1995; 56(23-24):2097-102. PubMed ID: 7776837
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Holdsworth MT; Raisch DW; Winter SS; Chavez CM
Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
[TBL] [Abstract][Full Text] [Related]
3. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Rosenberg SA
Cancer; 1981 Apr; 47(7):1746-51. PubMed ID: 6261926
[TBL] [Abstract][Full Text] [Related]
4. Nabilone: an alternative antiemetic for cancer chemotherapy.
Dalzell AM; Bartlett H; Lilleyman JS
Arch Dis Child; 1986 May; 61(5):502-5. PubMed ID: 3013104
[TBL] [Abstract][Full Text] [Related]
5. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Holdsworth MT; Raisch DW; Duncan MH; Chavez CM; Leasure MM
Ann Pharmacother; 1995 Jan; 29(1):16-21. PubMed ID: 7711340
[TBL] [Abstract][Full Text] [Related]
6. Review of cannabinoids and their antiemetic effectiveness.
Vincent BJ; McQuiston DJ; Einhorn LH; Nagy CM; Brames MJ
Drugs; 1983 Feb; 25 Suppl 1():52-62. PubMed ID: 6301800
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy induced nausea and emesis in pediatric cancer patients: external validity of child and parent emesis ratings.
Tyc VL; Mulhern RK; Fairclough D; Ward PM; Relling MV; Longmire W
J Dev Behav Pediatr; 1993 Aug; 14(4):236-41. PubMed ID: 8408666
[TBL] [Abstract][Full Text] [Related]
8. delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
Kluin-Neleman JC; Neleman FA; Meuwissen OJ; Maes RA
Vet Hum Toxicol; 1979 Oct; 21(5):338-40. PubMed ID: 516362
[TBL] [Abstract][Full Text] [Related]
9. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy.
Lucas VS; Laszlo J
JAMA; 1980 Mar; 243(12):1241-3. PubMed ID: 6244418
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS
Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994
[TBL] [Abstract][Full Text] [Related]
11. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues.
Carey MP; Burish TG; Brenner DE
Ann Intern Med; 1983 Jul; 99(1):106-14. PubMed ID: 6305249
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping.
Rock EM; Limebeer CL; Parker LA
Psychopharmacology (Berl); 2015 Dec; 232(24):4445-54. PubMed ID: 26381155
[TBL] [Abstract][Full Text] [Related]
13. Nausea and vomiting: Therapeutic orphans of pediatric oncology.
Bernhardt MB
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28561924
[No Abstract] [Full Text] [Related]
14. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Simon RM; Rosenberg SA
Ann Intern Med; 1979 Dec; 91(6):819-24. PubMed ID: 293141
[TBL] [Abstract][Full Text] [Related]
15. delta 9-tetrahydrocannabinol in clinical oncology.
Poster DS; Penta JS; Bruno S; Macdonald JS
JAMA; 1981 May 22-29; 245(20):2047-51. PubMed ID: 6262541
[TBL] [Abstract][Full Text] [Related]
16. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Frytak S; Moertel CG; O'Fallon JR; Rubin J; Creagan ET; O'Connell MJ; Schutt AJ; Schwartau NW
Ann Intern Med; 1979 Dec; 91(6):825-30. PubMed ID: 517882
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
[TBL] [Abstract][Full Text] [Related]
18. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Krcevski-Skvarc N; Wells C; Häuser W
Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.
Ono A; Kishimoto K; Hasegawa D; Goldman RD; Kosaka Y
Support Care Cancer; 2019 Mar; 27(3):895-899. PubMed ID: 30066198
[TBL] [Abstract][Full Text] [Related]
20. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
